Webcast of the ImmunoGen, Inc. Analyst and Investor Community Meeting on April 12, 2013

  Webcast of the ImmunoGen, Inc. Analyst and Investor Community Meeting on
  April 12, 2013

Business Wire

WALTHAM, Mass. -- April 11, 2013

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics, today announced that investors, journalists and the
general public are invited to listen to a live webcast of the Company’s
analyst and investor community meeting on April 12, 2013. The webcast will
begin at 8:30 a.m. ET and may be accessed through the Investor Information
section of the Company’s website, www.immunogen.com. The meeting is expected
to last approximately three hours, including a short break, and to contain
updated information related to the status of the Company’s IMGN901 NORTH Phase
II trial and its IMGN853 abstract submitted to ASCO. An archive of the webcast
will be available on the Company’s website through April 26, 2013.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
Targeted Antibody Payload (TAP) technology uses a tumor-targeting monoclonal
antibody to deliver one of ImmunoGen's highly potent cancer-cell killing
agents specifically to tumor cells. Ten TAP compounds are now in the clinic,
of which three are wholly owned by the Company. The most advanced compound
using ImmunoGen's TAP technology, KADCYLA (formerly T-DM1), has been approved
for marketing in the US and is undergoing regulatory review in Europe and
Japan; it is being commercialized in the US by Genentech, a member of the
Roche Group. More information about ImmunoGen can be found at
www.immunogen.com.

Contact:

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153
 
Press spacebar to pause and continue. Press esc to stop.